Abiopharma

🔍 Gallman Cari (Executive)

Company: BRISTOL MYERS SQUIBB CO (BMY)

Report Date: 2026-03-10

Detailed Transactions and Holdings:

• Acquired 912 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,978.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 102 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: J | equity_swap_involved: 0 | shares_owned_after: 11,876.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 415 shares of Common Stock, $0.10 par value at $60.13 per share (Direct)
  Date: 2026-03-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 11,461.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 867 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,328.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 94 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: J | equity_swap_involved: 0 | shares_owned_after: 12,234.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 396 shares of Common Stock, $0.10 par value at $60.13 per share (Direct)
  Date: 2026-03-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 11,838.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 5,201 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 17,039.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 2,554 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-03-10 | Code: J | equity_swap_involved: 0 | shares_owned_after: 14,485.00 | transaction_form_type: 4 | Footnotes: F6
• Sold 1,354 shares of Common Stock, $0.10 par value at $60.13 per share (Direct)
  Date: 2026-03-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 13,131.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 912 shares of Market Share Units (Derivative)
  Date: 2026-03-10 | Code: M | Expires: 2026-03-10 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F7, F1
• Sold 867 shares of Market Share Units (Derivative)
  Date: 2026-03-10 | Code: M | Expires: 2027-03-10 | equity_swap_involved: 0 | shares_owned_after: 867.00 | transaction_form_type: 4 | Footnotes: F7, F4
• Sold 5,201 shares of Performance Shares (Derivative)
  Date: 2026-03-10 | Code: M | Expires: 2026-03-10 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F8, F5
• Acquired 26,122 shares of Market Share Units (Derivative)
  Date: 2026-03-10 | Code: A | Expires: 2029-03-10 | equity_swap_involved: 0 | shares_owned_after: 26,122.00 | transaction_form_type: 4 | Footnotes: F9, F10
• Acquired 39,184 shares of Performance Shares (Derivative)
  Date: 2026-03-10 | Code: A | Expires: 2029-03-10 | equity_swap_involved: 0 | shares_owned_after: 39,184.00 | transaction_form_type: 4 | Footnotes: F11, F11

Footnotes:

• F1: Represents vesting of one-quarter of market share units granted on March 10, 2022.
• F2: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor.
• F3: Shares withheld for payment of taxes upon vesting of awards.
• F4: Represents vesting of one-quarter of market share units granted on March 10, 2023.
• F5: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award.
• F6: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board.
• F7: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%.
• F8: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2026.
• F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout.
• F10: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board.
• F11: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board.
• REMARKS: Exhibit 24 - Power of Attorney